
==== Front
Cancer Immunol Immunother
Cancer Immunol Immunother
Cancer Immunology, Immunotherapy : CII
0340-7004
1432-0851
Springer Berlin Heidelberg Berlin/Heidelberg

38564002
3665
10.1007/s00262-024-03665-x
Review
Bifidobacterium modulation of tumor immunotherapy and its mechanism
Pei Bo 12
Peng Shixuan 3
Huang Chuying 245
Zhou Fuxiang happyzhoufx@sina.com

1
1 https://ror.org/01v5mqw79 grid.413247.7 0000 0004 1808 0969 Hubei Key Laboratory of Tumor Biological Behaviors, Department of Radiation Oncology and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center, Wuhan, China
2 grid.507043.5 Department of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, China
3 https://ror.org/03mqfn238 grid.412017.1 0000 0001 0266 8918 Department of Oncology, Graduate Collaborative Training Base of The First People’s Hospital of Xiangtan City, Hengyang Medical School, University of South China, Hengyang, China
4 https://ror.org/01s12ye51 grid.507043.5 0000 0005 1089 2345 Hubei Selenium and Human Health Institute, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China
5 Hubei Provincial Key Laboratory of Selenium Resources and Bioapplications, Enshi, China
2 4 2024
2 4 2024
5 2024
73 5 9429 11 2023
29 2 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The advent of tumor immunotherapy in patients has revolutionized the treatment of tumors and significantly improved survival rates for a wide range of tumors. However, the full therapeutic potential of immune checkpoint inhibitors (ICIs) has yet to be realized, as not all patients have a lasting survival benefit from them, and a significant proportion of patients show primary or acquired resistance to immunotherapy. Bifidobacterium is one of the most common probiotics, and its antitumor and immunomodulatory effects have been demonstrated in recent years, but its immunomodulatory effects in tumors, especially on ICIs and in combination, have not been extensively studied in clinical practice, and its effects on the immune system and the mechanisms that modulate immunotherapy are largely unknown. Therefore, this review will focus on the immunomodulatory effects of Bifidobacteria in malignancies and the possible mechanisms of action of Bifidobacteria on immunotherapy in the hope of providing a basis for further research and better application of Bifidobacteria in clinical practice.

Keywords

Bifidobacterium
Immunotherapy
Immune checkpoint inhibitors
Gut probiotics
Mechanism
Natural Science Foundation of Enshi Tujia and Miao Autonomous Prefecture GovernmentD20220060 Pei Bo National Natural Science Foundation of ChinaNo. 81660503, 82160490 No. 81660503, 82160490 Huang Chuying Zhou Fuxiang Natural Science Foundation of Hubei Province2022BCE005 Zhou Fuxiang issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

Cancer is one of the world’s deadliest diseases, with morbidity and mortality rates increasing rapidly [1, 2]. In both men and women, cancer is the primary killer between the ages of 40 and 79 for both genders, accounting for 21% of fatalities worldwide, and between the ages of 60 and 79, cancer is the top killer [3, 4]. Other studies proved that many patients are less likely to receive guideline-consistent care, even when patient comorbidities are taken into account [5–7]. In addition, many patients are not only less likely to undergo surgery, but often rarely receive invasive treatments, as most cancer-directed therapies do not extend survival beyond the potential adverse effects and impact on quality of life, and so are not suitable for some patients [8, 9]. Of these, the third most prevalent cancer diagnosed worldwide is colorectal cancer, and its incidence is rising in low- and middle-income countries [10].

Although a variety of treatments have been applied to cancer over the past few decades, including surgery, chemotherapy, radiotherapy and targeted therapy, the prognosis remains unsatisfactory [10]. Fortunately, the advent of tumor immunotherapy has revolutionized the treatment of tumors [11]. Tumor immunotherapy refers to the application of immunological principles and methods to specifically remove small residual tumor lesions, inhibit tumor growth, and break immune tolerance by activating immune cells in the body and enhancing the body’s anti-tumor immune response. This approach has been applied to the treatment of a variety of tumors. Specifically, immunotherapy has significantly improved survival rates for many types of tumors. Several clinical studies are currently underway, primarily in patients with metastatic melanoma, to assess the potential of probiotics transplantation to enhance immune checkpoint blockade therapy. Clinical trials are also underway for prostate cancer, gastrointestinal cancer, and mesothelioma. Researchers combining active bacteria and immunotherapy have found to enhance the anti-tumor response and improve survival in patients with metastatic renal cell carcinoma, a finding that suggests that modulating gut bacteria can enhance the potential of immunotherapy for cancer patients [12–18].

As advances in genetic engineering, medicine, and biology have increased the availability and efficacy of bacteria in the treatment of tumors, gut probiotics modulation can influence the host’s response to many types of cancer therapy, particularly immunotherapy [13, 17]. Immunotherapy is receiving increasing attention and is becoming a supportive tool for oncology treatment [19]. Bifidobacteria have a role in the prevention of intestinal cancer in healthy intestinal microbiota by influencing intestinal probiotics metabolism and enhancing the host immune response; adhering to and degrading potential carcinogens; altering intestinal probiotics; producing anti-cancer and anti-mutagenic substances; promoting intestinal motility and enhancing the host immune response; and influencing host physiological activity [20–22].

Probiotics can mediate the regulation of the growth of intestinal bacteria and fungi [23], adhering to the surface of the gastrointestinal tract, aiding in maintaining the host’s intestinal microbial balance [24, 25]. Directly or indirectly affecting the colonization and growth of bacteria, regulating cell proliferation, the immunoregulatory mechanisms of probiotics mainly include mucosal barrier function, enhanced phagocytic activity of macrophages, and promotion of IgA production [26]. Probiotics can regulate the host’s immune function through the production of enhanced intestinal mucosal barrier function, inhibition of pathogen growth and adhesion, regulation of immune cell activity, and promotion of immune factor production [27]. Probiotic intervention can change the diversity of intestinal microbiota and regulate the abundance level of microbial communities, demonstrating inhibitory effects on the growth of harmful microorganisms in the intestine, particularly the beneficial appearance of intestinal health-promoting bacteria, reflecting the physiological effects of the probiotic preparation. Previous studies have reported how microbial communities promote the recruitment of T cells in mouse organs [28]. Regarding the immune therapy of intestinal microorganisms and tumors, recent studies have reported related human data. In different categories of epithelial tumors (non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma), and malignant melanoma, certain intestinal microbial communities have predictive effects on the efficacy of immunotherapy. The phenotypes of responders and non-responders in immune response can be altered through microbial transplantation, with germ-free mice or mice pre-treated with antibiotics obtaining corresponding phenotypes after the transplantation of the fecal microbial community of responders or non-responders. Feeding specific strains of bacteria can allow non-responding mice to regain the responding phenotype [29–31]. Bifidobacteria has been shown to positively induce an anti-tumor immune response [32]. Researchers are becoming aware that the intestinal probiotics and the host are in a mutually beneficial symbiosis, and the intestinal probiotics can influence the state of the host’s immune system by interacting with the lymphoid tissues associated with the intestinal mucosa, promoting and regulating both innate and adaptive immunity [33].

Immune checkpoint inhibitors (ICIs) act on immune checkpoints to enhance the immune response or relieve immunosuppression. Recent research has demonstrated that immune checkpoint inhibitor medication is significantly influenced by gut probiotics [34]. Since not all patients have a durable survival advantage from ICIs and a sizable portion of patients exhibit primary or acquired immunotherapy resistance, the full therapeutic potential of ICIs is still not fully realized [35]. For instance, up to 50% of melanoma patients and 25–44% of non-small cell lung cancer patients have primary ICIs resistance [36–38]. Exploring novel approaches to enhance treatment response and overcome resistance to this potent medication presents a significant challenge in light of this. The gut microbiota plays crucial roles in the body, including those related to intestinal immunity, controlling the levels of secondary bile acids, and influencing the metabolites made in the gut [39, 40]. Imbalances in the gut microbiota may promote the development of a variety of local and systemic diseases and affect the efficacy of treatment. Therefore, appropriate modulation of the gut probiotics may help to prevent the progression and development of tumors, and it may be beneficial in supporting effective treatment. The makeup of the gut microbiota may be altered therapeutically by the use of fecal microflora transplantation (FMT), probiotics, prebiotics, and synbiotics, among other methods [39].

Probiotics are currently the most often employed substances to alter the intestinal probiotics in a number of situations. One of the most widely utilized probiotic ingredients is Bifidobacterium. Despite extensive research into Bifidobacterium’s probiotic abilities, its immunomodulatory role in tumors has not been extensively investigated [22, 41, 42]. The immunomodulatory effects of tumors have not been thoroughly studied, and it is unclear how much of an effect they have on the immune system. Based on the current state of research, synergistic development of basic and clinical research for clinical translation allows for effective translation of preclinical research models of immunotherapy into clinical application. In this review, we will discuss the immunomodulatory role of Bifidobacterium in malignancies and then describe the possible mechanisms of Bifidobacterium for immunotherapy, with the expectation of providing a basis for further research on Bifidobacterium and better applications in clinical practice.

Advances in preclinical and clinical studies of Bifidobacterium-modulatory immunotherapy

Bifidobacterium colonies are small, smooth, convexly rounded, with intact margins, and creamy to white in color and play a significant role in the maturation of the immune system [43–46]. Bifidobacteria have been shown to have significant antitumor effects. Dynamic monitoring of fecal bacterial levels in tumor-bearing mice using 16S ribosomal RNA gene sequencing revealed that Bifidobacterium significantly delayed the growth of tumors in mice [47]. Bifidobacterium exerts this effect in three main ways: First, the immune system is activated by Bifidobacterium, which is consistent with its immunological-enhancing role. Second, it affects the gut probiotics biochemical metabolism, which reduces the production of carcinogens. Finally, Bifidobacterium has the ability to cause apoptosis in tumor cells, maintaining a normal cell phenotype and halting the development of tumors [48–52] (Fig. 1).Fig. 1 Bifidobacterium-modulatory cancer immunotherapy

A balanced symbiotic microbiota is necessary for an appropriate response to tumor therapy, according to studies. This microbiota’s control over the action of myeloid-derived cells in the TME is what makes this therapy effective [53]. Immune checkpoint inhibitors, which start an efficient tumor attack by disabling the body’s immune system’s safety mechanism, represent a significant advance in the treatment of tumors [54, 55]. Intestinal probiotics significantly enhance anti-tumor CD8+ T-cell immunity, especially Bifidobacterium [32].

Given the possible synergy between Bifidobacteria and immunotherapy, a number of animal model studies and preclinical studies related to this area have emerged in recent years. For example, by contrasting the diversity and makeup of the fecal microbiota in responders and non-responders, one researcher looked at the relationship between the gut microbiota and treatment response in patients receiving PD-1/PD-L1 blocking, and although the specific bacterial species required for the effects of a PD-1 blockade have not been identified, an acceptable response to anti-PD-1 treatment was substantially correlated with the presence of microorganisms from the species Bifidobacterium [48]. Sivan et al. explored the difference in efficacy between two mouse models of melanoma (JAX/TAC) with different intestinal commensal probiotics treated with antibodies targeting PD-L1 (αPD-L1 mAb) and found that Bifidobacterium spp. were significantly increased in JAX mice with slow tumor growth and a better response to PD-L1 blockade treatment [47]. The antitumor effectiveness of PD-L1 blockade was improved by oral delivery of probiotics, may be able to induce positive antitumor immune effects [55]. B. pseudolongum monoculture colonization in combination with ICIs treatment significantly enhanced splenic Th1 cell activation and effector function compared to Colidextribacter control colonized mice, as evidenced by IFN-γ production. B. pseudolongum induces Th1 differentiation and activates Th1 effector T cells together with CTLA-4 antibody [56]. A study by Gopalakrishnan et al. [57] found that Bifidobacterium bifidum may boost anti-tumor immunity and increase the effectiveness of anti-PD-L1 treatment in a mouse model of melanoma. In addition, Bifidobacterium vector-based oral cancer vaccine combination of anti-PD-1 and anti-CTLA-4 antibodies was enhanced in a mouse model of renal cell carcinoma [58].

Several clinical studies have proven the association between Bifidobacteria and the efficacy of tumor immunotherapy and the alleviation of adverse immune reactions. Oral live Bifidobacteria supplementation had a positive impact on patients undergoing colorectal cancer resection in terms of intestinal microbiota composition, immune system traits, and prognosis, according to a study by Zhang and colleagues [59]. Sixty patients were included in this study and randomly divided into two groups: the treatment group received enteral nutrition and oral live Bifidobacteria supplementation prior to surgery, and the control group received enteral nutrition only. Both preoperative and postoperative Bifidobacterium/E.coli (B/E) ratios in the control group (0.72 ± 0.14, 0.02 ± 0.06) were significantly lower than those in the treatment group (p < 0.05). On day 9 after surgery, the treatment group had higher fecal sIgA (secretory immunoglobulin A) levels and mucosal dendritic cell-mediated mucosal surfaces with anti-inflammatory properties. Zhang et al. also noted lower serum concentrations of IL-6, IgG, IgA, IgM, and CRP in the treatment group (p < 0.05). Additionally, compared to the control group, the therapy group experienced fewer postoperative septic problems. The number of additional hospital stays and hospital stay times were comparable. In addition to improving intestinal immunity and lowering postoperative problems, Bifidobacterial supplementation administered prior to colorectal cancer surgery may change the composition of the intestinal microbiota and help to restore its equilibrium [59].

In an open-label, single-center study (NCT03829111), 58% of metastatic renal cell carcinoma (RCC) patients received CBM588 (a live bacterial product containing Clostridium butyricum) combined with ICIs, compared with only ICIs treatment in 20% of patients. Furthermore, among patients treated with CBM588, PFS was significantly increased to 12.7 months compared to 2.5 months with ICIs alone [60]. Similarly, a preclinical and clinical investigation that generated a hypothesis implies that a combination of many commensal strains, including Bifidobacterium, also calls for additional clinical testing [46]. Nevertheless, despite the initial success of CBM588 as stated above, it is still unknown whether this whole strategy is feasible and effective [60]. Current oncology treatments are being combined with a number of experiments evaluating microbiome or targeted microbial methods, and the outcomes of these trials are highly anticipated [61]. Although the final results of these clinical trials have yet to be reported, this combination treatment strategy has shown significant efficacy in non-oncology diseases such as Clostridium difficile colitis and promises to have a clear advantage over FMT in optimizing long-term commitment to gut microbiota modulation in oncology treatment [61–63]. Overall, these findings suggest that Bifidobacterium may promote CTLA-4 blockade and PD-1/PD-L1, improving efficacy against ICIs and promoting tumor control.

Bifidobacteria not only show synergistic effects in combination with immune checkpoint inhibitors, but also play a positive role in reducing immune-induced adverse reactions. ICIs act on different organs throughout the body, and different organs may be targets for immune-mediated adverse reactions, with ulcerative colitis being one of the more common side effects. Although colitis and diarrhea have been recorded, PD-1 antibody therapy has fewer side effects than CTLA-4 antibody therapy. Ipilimumab, a CTLA4 antibody under development, has been linked to a variety of immune-mediated toxicities, including hepatitis, small bowel colitis, and skin reaction [63–65]. Drug-induced diarrhea (27–54%) and chronic colitis (8–22%) were linked to the use of ipilimumab and tremelimumab, two CTLA4 antibodies [66–70]. Therefore, researchers started studies to comprehend the involvement of the gut microbiota in the development of ulcerative colitis in patients receiving ipilimumab treatment. Researchers found that Bifidobacteria played a large role in improving the immunopathology associated with CTLA4 blockade but had no significant effect on the antitumor treatment itself [71]. The study established a mouse model of checkpoint blockade-associated autoimmunity by injection of anti-CTLA4 antibodies or isotype controls to test the response of mice to oral dextran sodium sulfate (DSS) and showed that disease was particularly severe in mice receiving 3% DSS and in mice receiving anti-CTLA4 antibodies. Histological sections of the colon of mice stained with hematoxylin and eosin showed increased proliferative inflammatory cell infiltration and ulceration and worse histopathological scores in the combination treatment group compared to the control group. The therapeutic effects of anti-CTLA4 antibodies in mice with melanoma were also observed in experiments in which data from colitis and tumor models were compared to mice receiving anti-CTLA4 antibodies similar to ipilimumab patients, consistent with clinical observations. Another study examined the effect of vancomycin in combination with DSS and anti-CTLA4 and showed that mice in the combination treatment group had significantly lower histopathology scores than those in the control group [72]. A study by Wang et al. revealed the important role of Bifidobacteria in reducing the incidence of colitis caused by CTLA4 blockade and found that vancomycin treatment enhanced the safety of colitis in mice treated with DSS + anti-CTLA-4. In addition, this study showed that Bifidobacterium reduced autoimmunity linked to anti-CTLA4 therapy and restored vancomycin-induced microbiota imbalance by downregulating several proteins such as KC, IL-6, and CFS3 [71]. Maruya et al. analyzed the role of PD-1 on the intestinal microbiota and discovered that PD-1−/− mice with Bifidobacterium were significantly reduced. In addition, IgA synthesis improved the growth of beneficial and homeostasis-inducing microorganisms in the gut and offered defense against the emergence of autoimmune disorders [73].

Bifidobacterium is a genus of gram-positive bacteria that are rod-shaped, sometimes bifurcated at one end, single or arranged in a V-shape, fenestrated, stellate, nonacid-resistant, nonbudding, nonmotile, and exclusively anaerobic. Bifidobacteria inhibit tumor growth. This effect is achieved in three main ways: by activating the immune system, regulating the metabolism of intestinal probiotics to reduce the production of carcinogens, and inducing apoptosis in tumor cells, which hinders tumor development.

Related mechanisms of Bifidobacteria in modulatory immunotherapy

The characteristics of Bifidobacterium that reduce the side effects of ICIs tumor immunotherapy and enhance the combined therapeutic effect of multiple immune checkpoint antibodies will help optimize relevant clinical immunotherapy protocols, laying a solid theoretical foundation for the use of probiotic strains to improve the structure of the intestinal probiotics and enhance the comprehensive effect of tumor immunotherapy [74].

The specific mechanism by which Bifidobacterium or other commensal bacteria stimulate anti-tumor immune responses is still unknown, despite the fact that it has been demonstrated that Bifidobacterium can enhance immunotherapeutic efficacy as a commensal organism capable of stimulating and modulating specific pathways through which it can influence the host’s innate and adaptive immune responses [43, 44, 75, 76]. Several studies have shown that Bifidobacterium modulates the immune function and inhibits tumor cell proliferation by possibly regulating different pathway mechanisms, among others [56, 77–79]. (Table 1) Several aspects of its possible mechanisms are described below (Fig. 2).Table 1 Clinical and mechanistic advances in cancer associated with Bifidobacterium research

Major finding	Cancer/Therapy	Mouse/Human data	Classification	References	
Microbiota-derived STING agonists induce intra-tumoral monocyte production of type I. IFN (IFN-I) to modulate macrophage polarization and NK-DC crosstalk	Melanoma/ICIs therapy	Mouse/Human	Microbiota-derived STING agonists and their effects on tumor immunity	[53]	
Bifidobacteria promote local anti-CD47 immunotherapy in tumor tissue through their ability to accumulate in the tumor microenvironment. Systemic administration of Bifidobacterium leads to its accumulation within tumors and converts non-responsive mice into responders to anti-CD47 immunotherapy with stimulation of the interferon gene (STING) and interferon-dependent manner. Local delivery of Bifidobacterium was effective in stimulating STING signaling and increased cross-initiation of dendritic cells after anti-CD47 treatment	Colon cancer/Immunotherapy	Mouse	[77]	
Bifidobacterium longum (BL-Tum) with pBBAD-Tum showed significant anti-tumor effects in tumor-bearing mice. The weight, volume, growth, MVD and vascular endothelial cell apoptosis of transplanted tumors in tumor-bearing mice treated with Tum-transformed Bifidobacterium longum (BL-Tum) were significantly lower than those in GFP-negative controls	Colon carcinoma	Mouse	Specific Bifidobacterium species and their effects on tumor growth, as well as their interactions with immunotherapy or checkpoint blockade	[80]	
16S ribosomal RNA sequencing identified Bifidobacterium bifidum as being associated with antitumor effects. Oral bifidobacteria alone improved tumor control to the same extent as programmed cell death protein 1 ligand 1 (PD-L1)-specific antibody therapy (checkpoint blockade), whereas combination therapy virtually eliminated tumor growth	Melanoma/Immunotherapy	Mouse	[47]	
Combination of Bifidobacterium infantis and adriamycin-supportive immunotherapy has a favorable anti-tumor effect on mouse mammary carcinoma	Breast cancer/Immune-combination therapy	Mouse	[50]	
The bifidobacterial product CBM588 improves clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab-ipilimumab	Metastatic renal cell carcinoma/nivolumab and ipilimumab with or without daily oral CBM588	Human	[60]	
The efficient peripheral generation of antigen-specific populations of Treg cells in response to an individual’s microbiota provides important post-thymic education of the immune system to foreign antigens	N/A	Mouse	The role of microbiota in regulating Treg cell populations, influencing post-thymic education of the immune system, and modulating T-cell responses	[81]	
Median progression-free survival (mPFS) was significantly longer in patients with Bifidobacterium lactis compared to patients without detectable Bifidobacterium lactis in their feces at baseline. The presence of Bifidobacterium lactis was an independently favorable prognostic factor influencing PFS in patients receiving combination therapy	Non-small cell lung cancer/anti-PD-1 immunotherapy combined with chemotherapy	Human	[52]	
T cells targeting an epitope expressed in the commensal bacterium Bifidobacterium breve (B. breve) called SVYRYYGL (SVY) cross-reacted with the model neoantigen SIYRYYGL (SIY). Mice lacking Bifidobacterium breve had reduced SVY-reactive T cells compared to Bifidobacterium breve-colonized mice, and the T-cell responses could be shifted by SVY immunization or by co-housing Bifidobacterium-free mice with Bifidobacterium-colonized mice	Melanoma	Mouse	[82]	
Intestinal B. pseudogentian modulates enhanced immunotherapeutic responses by producing the metabolite inosine. Immunotherapy resulted in reduced intestinal barrier function, which increased systemic transport of inosine and activated anti-tumor T cells	Immune checkpoint blockade (ICIs) therapy	Mouse	Influence of the intestinal microbiota, including specific Bifidobacterium species, on immunotherapeutic responses, tumor immunity, and the development of colon or renal cell carcinoma	[56]	
Bifidobacterium bifidum rescued the immunopathology of mice to a large extent without a significant effect on antitumor immunity, an effect that may be dependent on regulatory T cells	Immunotherapy	Mouse	[71]	
Bifidobacterium infantis (LBB) administration reduces tumor incidence, multiplicity/count and volume by enhancing TLR2-improved intestinal mucosal epithelial barrier integrity and inhibiting apoptosis and inflammation, thereby modulating the intestinal microbiota and reducing the development of colon cancer	Colon cancer	Mouse	[78]	
Bifidobacterium longum 420 significantly increased the survival of mice carrying renal cell carcinoma tumors treated with anti-PD-1 and anti-CTLA-4 antibodies compared to mice treated with antibodies alone	Renal cell carcinoma/anti-PD-1 and anti-CTLA-4 therapy	Mouse	[58]	

Fig. 2 Modulatory effects of Bifidobacteria in cancer immunotherapy

Promoting dendritic cell-dependent Th1 differentiation

Niers et al. [82] investigated the ability of probiotics to interact with neonatal dendritic cells (DCs) and identified the involvement of Bifidobacterium bifidum W23 in driving the initiation of Th1 and Tr1 responses in human neonatal DCs. A study by Mager et al. [56] used an animal model of colorectal cancer to identify bacteria that promote the efficacy of ICIs. The researchers found that Bifidobacterium pseudolongum provided the strongest facilitation of immune checkpoint blockade, and in the absence of ICI treatment, Bifidobacterium pseudolongum failed to induce anti-tumor immunity, but in small intestinal lamina propria CD4+ T cells, Bifidobacterium induced an increase in the expression of the Th1 master transcriptional regulator T-bet, suggesting that B. pseudobifidum has immunomodulatory capacity even in the absence of ICIs. Another research conducted by Li showed oral administration of Bifidobacterium breve (B. breve) lw01 could significantly up-regulate tumor cell apoptosis and inhibit tumor growth, which relied on the recruitment of DCs and tumor-infiltrating lymphocytes in tumor microenvironment. One of the mechanisms is the enhancement of interleukin 12 (IL-12) secretion derived from DCs is essential to B. breve’s antitumor effect, which was counteracted by the treatment of neutralizing antibody for IL-12 [83]. A more in-depth study of the ability of B. pseudobifidum to induce Th1 transcriptional differentiation during steady state and the mechanisms that activate Th1 effector function following treatment with ICIs revealed that the promotion of ICIs by B. pseudobifidum is mediated by inosine and is specifically dependent on adenosine 2A receptor (A2AR) signaling in T cells. The effect of inosine as a bacterial metabolite on T cells requires synergistic stimulation of DC (possibly via DCs), interleukin-12 (IL-12) receptors involved in Th1 differentiation and IFN-7 production for effective anti-tumor immunity. Bifidobacterium pseudobifidum enhances the role of ICIs in a mouse intestinal tumor model by enhancing conventional dendritic cell-dependent Th1 cell circuits. The immunomodulatory effects of Bifidobacterium longum KACC 91563 were investigated in mouse splenocytes and macrophages by Choi et al. This strain’s ability to control T and B cell proliferation was noted. Additionally, it prevented the proper balance of Th1/Th2 cytokines (i.e., Th2: IL-10, IL-4 and Th1: TNF-α, IL-2). IgE levels were increased following the use of Bifidobacterium longum KACC 91563. Therefore, this strain appears to have the ability to regulate the host immune system by producing IgE and acting by preserving and enhancing the Th1/Th2 balance [84]. The ability of three strains to modify known Th2 responses was evaluated by researchers in a tolerance induction model experiment in which Bifidobacterium bifidum NCC 453 promoted sublingual immunotherapy in a mouse model. They observed that these strains demonstrated polarized responses toward a Th1/Treg pattern and induced DC maturation [85]. Bifidobacterium bifidum can stimulate interleukin-12 (IL-12) production followed by enhanced recruitment of tumor-specific cytotoxic T lymphocytes (CTLs) and concomitant release of interferon-gamma (IFN-γ) [86, 87]. To clarify the many pathways connecting these signaling molecules, more research is needed.

Enhancing CD8 + T cell activity

Sivan et al. [47] originally showed in animal studies that the gut microbiota might influence the tumor immune microenvironment because Bifidobacterium bifidum improved DC activity, which improved CD8+ T cell initiation and anti-PD-L1 efficacy. Leads to high percentage of CD8+ T cells, which contributes to the effectiveness of anti-PD-1 therapy [29, 57, 88].

Bifidobacterium was strongly linked to the accumulation of activated antigen-specific T cells in the tumor microenvironment [47]. Bifidobacterium was positively associated with delayed tumor growth and a good response to anti-PD-L1 treatment. High activation of tumor-specific T cells around the tumor and an increase in antigen-specific CD8+ T cells inside the tumor were both associated with considerably better tumor control in Bifidobacterium-treated mice compared to non-Bifidobacterium-treated mice. Supplementation with an oral probiotic containing Bifidobacterium spp. was also found to restore the anti-PD-L1 therapeutic effect in mice with “dysregulated” intestinal probiotics [89]. When investigating the mechanism of action, a significant expansion of CD8+ SIY-specific 2C T cells was observed in the tumor-draining lymph nodes of JAX mice and Tac mice treated with Bifidobacterium, as well as a significant production of IFN-7. This suggests an improved DC immune response upstream of T cells, consistent with an increased proportion of MHC-II hiDCs in the tumors of both mice. Examination of genome-wide transcripts of early tumor-infiltrating DCs in Tac mice, JAX mice and Bifidobacterium-treated Tac mice revealed that the expression of 760 genes was upregulated in DCs from JAX mice and Bifidobacterium-treated Tac mice, significantly enriched in cytokine–cytokine receptor interactions, T-cell activation and monocyte proliferation positive regulatory pathways, many of which are involved in co-stimulation [CD40, CD70, H2M2 (MHC-I) ICAM1] and CD8+ T cell activation, DC maturation (IFNGR2, RELB), antigen presentation and cross-presentation (TAPBP, RAB27A, SLC1 1A1), chemokine-mediated immune cell in the tumor microenvironment enrichment (CXCL9, CX3CL1, CXCR4), and type 1 IFN signaling pathway (IRF1, IFNAR2, OAS2, IFI35, IFITM1). DCs isolated from these 3 pups were found to induce proliferation of CD8+ T SIY-specific 2C T cells at lower antigen concentrations in DCs from Bifidobacteria-treated Tac mice and JAX mice compared to Tac mice. Moreover, DCs from JAX mice elevated IFN-7 production by T cells at any antigen concentration. This suggests that signaling produced by commensal Bifidobacterium can stably modulate DC activation, thereby improving the effector function of tumor-specific CD8+ T cells [47]. Subsequently, Matson et al. [29] examined stool specimens from metastatic melanoma patients prior to anti-PD-1 immunotherapy and found that stool samples from patients responding to anti-PD-1 treatment were enriched for Bifidobacterium longum, Escherichia coli and Enterococcus faecalis. Transferring the feces from patients to germ-free mice showed that mice receiving feces from patients who had responded to anti-PD-1 treatment had slower tumor growth and significantly higher efficacy of anti-PD-L1 immunotherapy compared to mice receiving feces from patients who had not responded to anti-PD-1 treatment. The effect was mediated by an increase in CD8+ T cells and a decrease in FoxP3+ Treg cells in the tumor microenvironment. This approach was found to inhibit tumor growth in a homozygous mouse bladder cancer model using a Bifidobacterium vector-based oral cancer vaccine. Intercellular cytokine staining (ICCS) data suggest that Bifidobacterium longum 420 induces activated CD8+ and CD4+ T cells in the spleen and MLN and may activate dendritic cells (DCs) and Peyer ‘s patches (PPs) in mesenteric lymph nodes (MLNs) [90]. Furthermore, a recent study revealed that molecular mimicry between Bifidobacterium-derived epitopes and melanoma may favor activation of cross-reactive T cells and constitutes one of the mechanisms by which gut microbiota affects antitumor efficacy and modulates OVs response [91].

CD47 is a signaling molecule that helps tumor cells escape the immune system, and it has been found that blocking CD47 can have a beneficial effect on tumor immunotherapy [56, 92]. Researchers have shown that intestinal probiotics can further stimulate the body to produce anti-CD47 antibodies by activating the STING signaling pathway [56]. Experimentally, wild-type (WT) mice, antibiotic-fed mice and germ-free (GF) mice from different institutions differed in their immune anti-tumor effects against CD47. GF mice differed in their immune antitumor effects against CD47. The anti-tumor response to CD47 blockade treatment in non-responding mice (Tac mice) was restored by contact transmission or oral transfer of commensal bacteria from responding Jax mice through mouse cohabitation. Subsequent results from Bifidobacterium injections showed antitumor efficacy in mice that did not respond to anti-CD47 treatment. It suggests the tumor-targeting ability of Bifidobacterium is a possible mechanism by which the intestinal probiotics affects the antitumor response. The antitumor effects of CD47 blockers are dependent on type I IFN signaling and cross-initiation of tumor-associated DCs. I-IFN receptor-blocking antibody to Tac mice and discovered that blocking type I IFN signaling prevented the administration of anti-CD47 therapy even in the presence of Bifidobacterium, highlighting the significance of type I IFN signaling in DCs for the treatment of CD47 blockade caused by Bifidobacteria. Subsequently, to observe the effect of Bifidobacterium on type I IFN signaling in DCs, researchers assessed IFN-P expression in isolated tumor DCs. IFN-P expression was increased in DCs from Tac mice treated with Bifidobacterium and anti-CD47, but not in mice treated with anti-CD47. Type I IFN signaling promotes the cross-initiation of DCs and stimulates adaptive immune responses [93, 94]. The STING pathway regulates type I IFN expression in anti-CD47-mediated antitumor effects [56, 94]. However, it is still unclear how the STING pathway is related to Bifidobacterium’s antitumor activity. In Tmeml73-/- mice with the STING gene knocked down, it was found that the use of Bifidobacterium failed to support anti-CD47 immunotherapy. As a result, the STING signaling pathway is essential for Bifidobacteria’s antitumor actions [56]. Specific members of the intestinal probiotics can enhance the antitumor efficacy of immunotherapy by colonizing tumor sites. An anaerobic commensal bacterium found in the gastrointestinal tract, Bifidobacterium, has the ability to infiltrate the interior of tumors and control the immune response induced by CD47 inhibition. Bifidobacterium bifidum has the potential to be an effective clinical target for tumors, given its characteristics [56].

Inducing immune responses against microbial antigens that cross-react with tumor-associated antigens

A related study found that B. bifidum PRL2010 sortase-dependent bacterial hairs inhibited the expression of additional pro-inflammatory cytokines linked to systemic responses, such as IL-12, while activating a variety of signals in macrophages by locally producing high amounts of the cytokine TNF-. Apparently, this facilitated a close association between the host immune cells and Bifidobacterium strain [95]. This may be an important aspect of Bifidobacterial regulation of immunity that warrants further investigation. SVYRYYGL(SVY) peptides placed on mouse MHC (Major Histocompatibility Complex) bound to a model TCR (T-cell receptor) specific for the KbSIY complex, but in a different conformation, according to investigations using molecular dynamics simulations by Catherine A. Bessell et al. With a preference for either SIY or SVY, heterozygous CD8+ T cell populations grown from wild-type C57BL/6 mice reacted cross-reactively with bacterial and tumor antigens. One of their study’s most intriguing conclusions was that the gut microbiota induced T-cell responses that were SVYRYYGL (SVY)-reactive. Analysis of mice with and without Bifidobacterium demonstrated that in vivo initiation occurred and improved the ability to increase SVY-reactive T cells, even though the mechanisms of T cell activation and selection by components of the gut microbiota remain unknown. Due to their immunogenicity, T cells targeting an epitope called SVYRYYGL (SVY) expressed in the symbiotic bacterium Bifidobacterium breve cross-react with the model neoantigen SIYRYYGL (SIY). T-cell responses that are specific for an antigen are also metastable [96]. Laurence Zitvogel and Guido Kroemer summarize evidence that microbial/tumor cross-reactive immune responses are clinically relevant, particularly when the microbes are part of the gut microbiota. The gut microbiota affects host physiology at multiple levels, reflecting the complexity of ecosystem changes in which microbial species may influence immune tone by acting on metabolic pathways, neuroendocrine circuits, and pathogen recognition receptors [97].

Currently, it is uncertain how T cell populations are affected by homologous epitopes between tumors and the microbiota. As a result, mechanistic studies must focus on how cross-reactive T-cell populations react to tumor cells and how bacterial colonization affects cross-reactive T-cell populations to gain insight into the antigens expressed by the microbiota and their potential cross-reactivity with T cells that recognize tumor-specific neoantigens.

The regulatory mechanisms of Bifidobacteria in cancer immunotherapy involve three main aspects: In the tumor immune microenvironment, Bifidobacterium intestinalis promotes dendritic cell-dependent Th1 differentiation; enhances CD8+ T cell activity to modulate the immune response; and induces immune responses against microbial antigens that cross-react with tumor-associated antigens.

Summary and outlook

Antitumor medications and the gut microbiota interact in a very complex way through pharmacodynamics and pharmacokinetics (e.g., enzymatic degradation and metabolism). At the same time, tumor immunotherapy can alter the composition of the microbiota, producing bidirectional interactions [98]. Bifidobacteria have been shown to selectively accumulate in tumors upon entry into the blood stream, possibly due to the hypoxic microenvironment’s eosinophilic nature and immunosuppressive conditions for bacterial colonization and proliferation [47]. Bifidobacteria improved anti-cancer immune monitoring and increased the abundance of tumor-infiltrating CD8+ T cells [47]. Thus, Bifidobacterium is considered a promising delivery vehicle for tumor-specific transport [99]. In future bioengineering research, genetic improvement of Bifidobacterium strains and strengthening the development and exploitation of Bifidobacterium preparations will provide new ideas and methods for future tumor research and tumor treatment.

Bifidobacteria have been shown to increase efficiency and reduce side effects in tumor immunotherapy, but the underlying mechanisms of action are unclear. Understanding the relationship between Bifidobacteria and immunotherapy is gaining popularity because it may have a substantial impact on the effectiveness and safety of some anti-cancer medications as well as the creation of effective, individualized clinical therapies. Most of the current findings are derived from studies conducted in animal models, and further research should focus on clinical combinations with other antitumor therapeutic modalities as well as on the impact of Bifidobacterium bifidum in combination with ICIs on overall cancer survival and on interactions with other treatments. The effect of Bifidobacterium on host immunity is considered one of the important factors influencing antitumor immunity and therapeutic efficacy. The current clinical approach of using microbial agents with immunotherapeutic effects (e.g., probiotic strains such as Bifidobacterium bifidum) to enhance the efficacy of cancer immunotherapy is still in its infancy, and in future research, a deeper understanding of the mechanisms of microbial modulation of immunity and identification of immunostimulatory and immunosuppressive related bacterial strains could improve the feasibility and efficacy of therapeutic approaches, thereby increasing tumor cure rates [100].

The rapid development of tumor immunity has brought new light to the cure of tumors, and as research continues, the understanding of the mechanisms of tumor development and the complex relationship between its organism’s immune system is becoming clearer. Immunotherapy holds promise as an ideal treatment for cancer patients. At this stage, more standardized and unbiased pre-clinical and clinical studies are needed to ensure that the treatment effect is sufficiently reliable and significant in the bidirectional relationship between immunotherapy and the human gut microbiota in cancer patients. The study of gut probiotics has benefited many patients, but as more and more research progresses, researchers are noticing that tumor immunotherapy is not a panacea, as there are still a large number of studies finding poor response, slow effect, drug resistance, and other problems after the organism has been given immunotherapy. Therefore, how to refine the therapeutic regimen of tumor immunity by modulating or intervening in tumor immunity to achieve greater clinical benefit for patients is unclear. This is an important direction for basic and clinical research.

Although Bifidobacteria open up a new avenue for tumor immunotherapy, there are still many challenges and limitations to the clinical applications that remain to be realized. This is because the ability of Bifidobacterium to be used directly as a biomarker for colorectal carcinomatosis still needs further clarification. An international standardization of methods for intestinal cohort collection and sequencing analysis is needed. Further research is still required for the synergistic development of basic and clinical studies to facilitate clinical translation.

The relationship between the gut microbiome and tumor immunotherapy is extremely complex. It is unclear which component of Bifidobacterium is the most ideal focus for tumor immunotherapy. Therefore, there is a need to develop multiple research programs in future clinical studies, such as fecal microbiome transplantation studies and dietary studies. Despite the important role of Bifidobacteria in tumor immunotherapy, the exact mechanism by which they trigger the immune response has not been fully investigated. Currently, most studies aimed at linking Bifidobacteria to immunomodulatory effects have been conducted using cell lines/animal models and therefore do not provide a comprehensive understanding of all the effects that Bifidobacteria have on the human immune system. Future research challenges therefore require more robust clinical trials to better understand the relationship between Bifidobacteria and tumor immunotherapy and the mechanisms underlying.

Author contributions

BP, SP and CH searched and analyzed the published literature and drafted the manuscript. FZ reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of China (No. 81660503, 82160490); Natural Science Foundation of Hubei Province (2022BCE005); and Natural Science Foundation of Enshi Tujia and Miao Autonomous Prefecture Government (D20220060).

Declarations

Conflict of interest

The authors declare no conflicts of interest.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Bo Pei and Shixuan Peng have contributed equally to this work.
==== Refs
References

1. Morgan E Arnold M Gini A Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN Gut 2023 72 2 338 344 10.1136/gutjnl-2022-327736 36604116
Morgan E, Arnold M, Gini A et al (2023) Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72(2):338–34436604116
2. Badowski C He B Garmire LX Blood-derived lncRNAs as biomarkers for cancer diagnosis: the good, the bad and the beauty NPJ Precis Oncol 2022 6 1 40 10.1038/s41698-022-00283-7 35729321
Badowski C, He B, Garmire LX (2022) Blood-derived lncRNAs as biomarkers for cancer diagnosis: the good, the bad and the beauty. NPJ Precis Oncol 6(1):4035729321
3. Siegel RL Wagle NS Cercek A Smith RA Jemal A Colorectal cancer statistics, 2023 CA Cancer J Clin 2023 73 3 233 254 10.3322/caac.21772 36856579
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A (2023) Colorectal cancer statistics, 2023. CA Cancer J Clin 73(3):233–25436856579
4. DeSantis CE Miller KD Dale W Cancer statistics for adults aged 85 years and older, 2019 CA Cancer J Clin 2019 69 6 452 467 10.3322/caac.21577 31390062
DeSantis CE, Miller KD, Dale W et al (2019) Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin 69(6):452–46731390062
5. LeMasters T Madhavan SS Sambamoorthi U Hazard-Jenkins HW Kelly KM Long D Receipt of guideline-concordant care among older women with stage I-III breast cancer: a population-based study J Natl Compr Canc Netw 2018 16 6 703 710 10.6004/jnccn.2018.7004 29891521
LeMasters T, Madhavan SS, Sambamoorthi U, Hazard-Jenkins HW, Kelly KM, Long D (2018) Receipt of guideline-concordant care among older women with stage I-III breast cancer: a population-based study. J Natl Compr Canc Netw 16(6):703–71029891521
6. Fang P He W Gomez DR Influence of age on guideline-concordant cancer care for elderly patients in the united states Int J Radiat Oncol Biol Phys 2017 98 4 748 757 10.1016/j.ijrobp.2017.01.228 28366580
Fang P, He W, Gomez DR et al (2017) Influence of age on guideline-concordant cancer care for elderly patients in the united states. Int J Radiat Oncol Biol Phys 98(4):748–75728366580
7. González Serrano A Martínez Tapia C de la Taille A Adherence to treatment guidelines and associated survival in older patients with prostate cancer: a prospective multicentre cohort study Cancers 2021 13 18 4694 10.3390/cancers13184694 34572921
González Serrano A, Martínez Tapia C, de la Taille A et al (2021) Adherence to treatment guidelines and associated survival in older patients with prostate cancer: a prospective multicentre cohort study. Cancers 13(18):469434572921
8. Edwards BK Noone AM Mariotto AB Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer Cancer 2014 120 9 1290 1314 10.1002/cncr.28509 24343171
Edwards BK, Noone AM, Mariotto AB et al (2014) Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120(9):1290–131424343171
9. Siegel RL Miller KD Wagle NS Jemal A Cancer statistics, 2023 CA Cancer J Clin 2023 73 1 17 48 10.3322/caac.21763 36633525
Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–4836633525
10. Siegel RL Torre LA Soerjomataram I Global patterns and trends in colorectal cancer incidence in young adults Gut 2019 68 12 2179 2185 10.1136/gutjnl-2019-319511 31488504
Siegel RL, Torre LA, Soerjomataram I et al (2019) Global patterns and trends in colorectal cancer incidence in young adults. Gut 68(12):2179–218531488504
11. Rosato PC Wijeyesinghe S Stolley JM Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy Nat Commun 2019 10 1 567 10.1038/s41467-019-08534-1 30718505
Rosato PC, Wijeyesinghe S, Stolley JM et al (2019) Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat Commun 10(1):56730718505
12. Ribas A Wolchok JD Cancer immunotherapy using checkpoint blockade Science 2018 359 6382 1350 1355 10.1126/science.aar4060 29567705
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350–135529567705
13. Xin YuJ Hubbard-Lucey VM Tang J Immuno-oncology drug development goes global Nat Rev Drug Discov 2019 18 12 899 900 10.1038/d41573-019-00167-9 31780841
Xin YuJ, Hubbard-Lucey VM, Tang J (2019) Immuno-oncology drug development goes global. Nat Rev Drug Discov 18(12):899–90031780841
14. Ma VT Daignault-Newton S Waninger JJ The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma Pigment Cell Melanoma Res 2021 34 3 629 640 10.1111/pcmr.12944 33128316
Ma VT, Daignault-Newton S, Waninger JJ et al (2021) The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma. Pigment Cell Melanoma Res 34(3):629–64033128316
15. de Castro G Jr, Kudaba I, Wu YL, et al. (2023) Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol 41(11):1986–1991
16. Rini BI Plimack ER Stus V Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma N Engl J Med 2019 380 12 1116 1127 10.1056/NEJMoa1816714 30779529
Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–112730779529
17. Zhang Z Pan Q Lu M Zhao B Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials EClinicalMedicine 2023 63 102156 10.1016/j.eclinm.2023.102156 37600482
Zhang Z, Pan Q, Lu M, Zhao B (2023) Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials. EClinicalMedicine 63:10215637600482
18. André T Lonardi S Wong K Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 Ann Oncol 2022 33 10 1052 1060 10.1016/j.annonc.2022.06.008 35764271
André T, Lonardi S, Wong K et al (2022) Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol 33(10):1052–106035764271
19. Filin IY Solovyeva VV Kitaeva KV Rutland CS Rizvanov AA Current trends in cancer immunotherapy Biomedicines 2020 8 12 621 10.3390/biomedicines8120621 33348704
Filin IY, Solovyeva VV, Kitaeva KV, Rutland CS, Rizvanov AA (2020) Current trends in cancer immunotherapy. Biomedicines 8(12):62133348704
20. Fu L Song J Wang C Fu S Wang Y Bifidobacterium infantis potentially alleviates shrimp tropomyosin-induced allergy by tolerogenic dendritic cell-dependent induction of regulatory T cells and alterations in gut microbiota Front Immunol 2017 8 1536 10.3389/fimmu.2017.01536 29176981
Fu L, Song J, Wang C, Fu S, Wang Y (2017) Bifidobacterium infantis potentially alleviates shrimp tropomyosin-induced allergy by tolerogenic dendritic cell-dependent induction of regulatory T cells and alterations in gut microbiota. Front Immunol 8:153629176981
21. Li M Ding J Stanton C Bifidobacterium longum subsp. infantis FJSYZ1M3 ameliorates DSS-induced colitis by maintaining the intestinal barrier, regulating inflammatory cytokines, and modifying gut microbiota Food Funct 2023 14 1 354 368 10.1039/D2FO03263E 36511157
Li M, Ding J, Stanton C et al (2023) Bifidobacterium longum subsp. infantis FJSYZ1M3 ameliorates DSS-induced colitis by maintaining the intestinal barrier, regulating inflammatory cytokines, and modifying gut microbiota. Food Funct 14(1):354–36836511157
22. Azad M Sarker M Li T Yin J Probiotic species in the modulation of gut microbiota: an overview Biomed Res Int 2018 2018 9478630 10.1155/2018/9478630 29854813
Azad M, Sarker M, Li T, Yin J (2018) Probiotic species in the modulation of gut microbiota: an overview. Biomed Res Int 2018:947863029854813
23. Bartolomaeus H Balogh A Yakoub M Short-chain fatty acid propionate protects from hypertensive cardiovascular damage Circulation 2019 139 11 1407 1421 10.1161/CIRCULATIONAHA.118.036652 30586752
Bartolomaeus H, Balogh A, Yakoub M et al (2019) Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation 139(11):1407–142130586752
24. Turroni F Ventura M Buttó LF Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective Cell Mol Life Sci 2014 71 2 183 203 10.1007/s00018-013-1318-0 23516017
Turroni F, Ventura M, Buttó LF et al (2014) Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective. Cell Mol Life Sci 71(2):183–20323516017
25. Wang Y Li N Yang JJ Probiotics and fructo-oligosaccharide intervention modulate the microbiota-gut brain axis to improve autism spectrum reducing also the hyper-serotonergic state and the dopamine metabolism disorder Pharmacol Res 2020 157 104784 10.1016/j.phrs.2020.104784 32305492
Wang Y, Li N, Yang JJ et al (2020) Probiotics and fructo-oligosaccharide intervention modulate the microbiota-gut brain axis to improve autism spectrum reducing also the hyper-serotonergic state and the dopamine metabolism disorder. Pharmacol Res 157:10478432305492
26. Meijnikman AS Gerdes VE Nieuwdorp M Herrema H Evaluating causality of gut microbiota in obesity and diabetes in humans Endocr Rev 2018 39 2 133 153 10.1210/er.2017-00192 29309555
Meijnikman AS, Gerdes VE, Nieuwdorp M, Herrema H (2018) Evaluating causality of gut microbiota in obesity and diabetes in humans. Endocr Rev 39(2):133–15329309555
27. Wan LY Chen ZJ Shah NP El-Nezami H Modulation of intestinal epithelial defense responses by probiotic bacteria Crit Rev Food Sci Nutr 2016 56 16 2628 2641 10.1080/10408398.2014.905450 25629818
Wan LY, Chen ZJ, Shah NP, El-Nezami H (2016) Modulation of intestinal epithelial defense responses by probiotic bacteria. Crit Rev Food Sci Nutr 56(16):2628–264125629818
28. Bullman S Pedamallu CS Sicinska E Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer Science 2017 358 6369 1443 1448 10.1126/science.aal5240 29170280
Bullman S, Pedamallu CS, Sicinska E et al (2017) Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358(6369):1443–144829170280
29. Matson V Fessler J Bao R The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients Science 2018 359 6371 104 108 10.1126/science.aao3290 29302014
Matson V, Fessler J, Bao R et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359(6371):104–10829302014
30. Derosa L Routy B Kroemer G Zitvogel L The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1 Oncoimmunology 2018 7 6 e1434468 10.1080/2162402X.2018.1434468 29872574
Derosa L, Routy B, Kroemer G, Zitvogel L (2018) The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. Oncoimmunology 7(6):e143446829872574
31. Desai MS Seekatz AM Koropatkin NM A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility Cell 2016 167 5 1339 1353.e21 10.1016/j.cell.2016.10.043 27863247
Desai MS, Seekatz AM, Koropatkin NM et al (2016) A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167(5):1339-1353.e2127863247
32. Li W Deng Y Chu Q Zhang P Gut microbiome and cancer immunotherapy Cancer Lett 2019 447 41 47 10.1016/j.canlet.2019.01.015 30684593
Li W, Deng Y, Chu Q, Zhang P (2019) Gut microbiome and cancer immunotherapy. Cancer Lett 447:41–4730684593
33. Maynard CL Elson CO Hatton RD Weaver CT Reciprocal interactions of the intestinal microbiota and immune system Nature 2012 489 7415 231 241 10.1038/nature11551 22972296
Maynard CL, Elson CO, Hatton RD, Weaver CT (2012) Reciprocal interactions of the intestinal microbiota and immune system. Nature 489(7415):231–24122972296
34. Choudhry H The microbiome and its implications in cancer immunotherapy Molecules 2021 26 1 206 10.3390/molecules26010206 33401586
Choudhry H (2021) The microbiome and its implications in cancer immunotherapy. Molecules 26(1):20633401586
35. Sharma P Hu-Lieskovan S Wargo JA Ribas A Primary, adaptive, and acquired resistance to cancer immunotherapy Cell 2017 168 4 707 723 10.1016/j.cell.2017.01.017 28187290
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4):707–72328187290
36. Gide TN Wilmott JS Scolyer RA Long GV Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma Clin Cancer Res 2018 24 6 1260 1270 10.1158/1078-0432.CCR-17-2267 29127120
Gide TN, Wilmott JS, Scolyer RA, Long GV (2018) Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res 24(6):1260–127029127120
37. Fehrenbacher L Spira A Ballinger M Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Lancet 2016 387 10030 1837 1846 10.1016/S0140-6736(16)00587-0 26970723
Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837–184626970723
38. Gandhi L Rodríguez-Abreu D Gadgeel S Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer N Engl J Med 2018 378 22 2078 2092 10.1056/NEJMoa1801005 29658856
Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–209229658856
39. Kaźmierczak-Siedlecka K Daca A Fic M van de Wetering T Folwarski M Makarewicz W Therapeutic methods of gut microbiota modification in colorectal cancer management-fecal microbiota transplantation, prebiotics, probiotics, and synbiotics Gut Microbes 2020 11 6 1518 1530 10.1080/19490976.2020.1764309 32453670
Kaźmierczak-Siedlecka K, Daca A, Fic M, van de Wetering T, Folwarski M, Makarewicz W (2020) Therapeutic methods of gut microbiota modification in colorectal cancer management-fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes 11(6):1518–153032453670
40. Kaźmierczak-Siedlecka K Dvořák A Folwarski M Daca A Przewłócka K Makarewicz W Fungal gut microbiota dysbiosis and its role in colorectal, oral, and pancreatic carcinogenesis Cancers 2020 12 5 1326 10.3390/cancers12051326 32455985
Kaźmierczak-Siedlecka K, Dvořák A, Folwarski M, Daca A, Przewłócka K, Makarewicz W (2020) Fungal gut microbiota dysbiosis and its role in colorectal, oral, and pancreatic carcinogenesis. Cancers 12(5):132632455985
41. Sánchez B Delgado S Blanco-Míguez A Lourenço A Gueimonde M Margolles A Probiotics, gut microbiota, and their influence on host health and disease Mol Nutr Food Res 2017 61 1 1600240 10.1002/mnfr.201600240
Sánchez B, Delgado S, Blanco-Míguez A, Lourenço A, Gueimonde M, Margolles A (2017) Probiotics, gut microbiota, and their influence on host health and disease. Mol Nutr Food Res 61(1):1600240
42. Azad M Sarker M Wan D Immunomodulatory effects of probiotics on cytokine profiles Biomed Res Int 2018 2018 8063647 10.1155/2018/8063647 30426014
Azad M, Sarker M, Wan D (2018) Immunomodulatory effects of probiotics on cytokine profiles. Biomed Res Int 2018:806364730426014
43. Alessandri G Ossiprandi MC MacSharry J van Sinderen D Ventura M Bifidobacterial dialogue with its human host and consequent modulation of the immune system Front Immunol 2019 10 2348 10.3389/fimmu.2019.02348 31632412
Alessandri G, Ossiprandi MC, MacSharry J, van Sinderen D, Ventura M (2019) Bifidobacterial dialogue with its human host and consequent modulation of the immune system. Front Immunol 10:234831632412
44. Hidalgo-Cantabrana C, Delgado S, Ruiz L, Ruas-Madiedo P, Sánchez B, Margolles A (2017) Bifidobacteria and their health-promoting effects. Microbiol Spectr 5(3)
45. Ruiz L Delgado S Ruas-Madiedo P Sánchez B Margolles A Bifidobacteria and their molecular communication with the immune system Front Microbiol 2017 8 2345 10.3389/fmicb.2017.02345 29255450
Ruiz L, Delgado S, Ruas-Madiedo P, Sánchez B, Margolles A (2017) Bifidobacteria and their molecular communication with the immune system. Front Microbiol 8:234529255450
46. Ngo N Choucair K Creeden JF Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology Future Oncol 2019 15 33 3861 3876 10.2217/fon-2019-0374 31668087
Ngo N, Choucair K, Creeden JF et al (2019) Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology. Future Oncol 15(33):3861–387631668087
47. Sivan A Corrales L Hubert N Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy Science 2015 350 6264 1084 1089 10.1126/science.aac4255 26541606
Sivan A, Corrales L, Hubert N et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084–108926541606
48. Iida N Dzutsev A Stewart CA Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment Science 2013 342 6161 967 970 10.1126/science.1240527 24264989
Iida N, Dzutsev A, Stewart CA et al (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342(6161):967–97024264989
49. Viaud S Saccheri F Mignot G The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide Science 2013 342 6161 971 976 10.1126/science.1240537 24264990
Viaud S, Saccheri F, Mignot G et al (2013) The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342(6161):971–97624264990
50. Akbaba M Gökmen GG Kışla D Nalbantsoy A In vivo investigation of supportive immunotherapeutic combination of Bifidobacterium infantis 35624 and doxorubicin in murine breast cancer Probiotics Antimicrob Proteins 2023 15 4 880 888 10.1007/s12602-021-09899-w 35112297
Akbaba M, Gökmen GG, Kışla D, Nalbantsoy A (2023) In vivo investigation of supportive immunotherapeutic combination of Bifidobacterium infantis 35624 and doxorubicin in murine breast cancer. Probiotics Antimicrob Proteins 15(4):880–88835112297
51. Legesse Bedada T Feto TK Awoke KS Garedew AD Yifat FT Birri DJ Probiotics for cancer alternative prevention and treatment Biomed Pharmacother 2020 129 110409 10.1016/j.biopha.2020.110409 32563987
Legesse Bedada T, Feto TK, Awoke KS, Garedew AD, Yifat FT, Birri DJ (2020) Probiotics for cancer alternative prevention and treatment. Biomed Pharmacother 129:11040932563987
52. Zhao H Li D Liu J Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients Cancer Med 2023 12 5 6325 6336 10.1002/cam4.5312 36205311
Zhao H, Li D, Liu J et al (2023) Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients. Cancer Med 12(5):6325–633636205311
53. Inaguma S Lasota J Czapiewski P CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness J Pathol 2020 250 2 205 216 10.1002/path.5361 31639216
Inaguma S, Lasota J, Czapiewski P et al (2020) CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. J Pathol 250(2):205–21631639216
54. Esfahani K Al-Aubodah TA Thebault P Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation Nat Commun 2019 10 1 4712 10.1038/s41467-019-12628-1 31624262
Esfahani K, Al-Aubodah TA, Thebault P et al (2019) Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nat Commun 10(1):471231624262
55. Tanoue T Morita S Plichta DR A defined commensal consortium elicits CD8 T cells and anti-cancer immunity Nature 2019 565 7741 600 605 10.1038/s41586-019-0878-z 30675064
Tanoue T, Morita S, Plichta DR et al (2019) A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565(7741):600–60530675064
56. Mager LF Burkhard R Pett N Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy Science 2020 369 6510 1481 1489 10.1126/science.abc3421 32792462
Mager LF, Burkhard R, Pett N et al (2020) Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369(6510):1481–148932792462
57. Gopalakrishnan V Spencer CN Nezi L Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients Science 2018 359 6371 97 103 10.1126/science.aan4236 29097493
Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97–10329097493
58. Ueki H Kitagawa K Kato M An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model Sci Rep 2023 13 1 9994 10.1038/s41598-023-37234-6 37340017
Ueki H, Kitagawa K, Kato M et al (2023) An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model. Sci Rep 13(1):999437340017
59. Zhang JW Du P Chen DW Cui L Ying CM Effect of viable Bifidobacterium supplement on the immune status and inflammatory response in patients undergoing resection for colorectal cancer Zhonghua Wei Chang Wai Ke Za Zhi 2010 13 1 40 43 20099160
Zhang JW, Du P, Chen DW, Cui L, Ying CM (2010) Effect of viable Bifidobacterium supplement on the immune status and inflammatory response in patients undergoing resection for colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi 13(1):40–4320099160
60. Dizman N Meza L Bergerot P Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial Nat Med 2022 28 4 704 712 10.1038/s41591-022-01694-6 35228755
Dizman N, Meza L, Bergerot P et al (2022) Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 28(4):704–71235228755
61. Lemon KP Armitage GC Relman DA Fischbach MA Microbiota-targeted therapies: an ecological perspective Sci Transl Med 2012 4 137 137rv5 10.1126/scitranslmed.3004183 22674555
Lemon KP, Armitage GC, Relman DA, Fischbach MA (2012) Microbiota-targeted therapies: an ecological perspective. Sci Transl Med 4(137):137rv522674555
62. Feuerstadt P Louie TJ Lashner B SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection N Engl J Med 2022 386 3 220 229 10.1056/NEJMoa2106516 35045228
Feuerstadt P, Louie TJ, Lashner B et al (2022) SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med 386(3):220–22935045228
63. Li D Li J Chu H Wang Z A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope MAbs 2020 12 1 1725365 10.1080/19420862.2020.1725365 32054416
Li D, Li J, Chu H, Wang Z (2020) A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope. MAbs 12(1):172536532054416
64. Ott PA Nazzaro M Pfaff KL Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial J Immunother Cancer 2021 9 11 e003318 10.1136/jitc-2021-003318 34772758
Ott PA, Nazzaro M, Pfaff KL et al (2021) Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. J Immunother Cancer 9(11):e00331834772758
65. Ma C MacDonald JK Nguyen TM Pharmacological interventions for the prevention and treatment of immune checkpoint inhibitor-associated enterocolitis: a systematic review Dig Dis Sci 2022 67 4 1128 1155 10.1007/s10620-021-06948-w 33770330
Ma C, MacDonald JK, Nguyen TM et al (2022) Pharmacological interventions for the prevention and treatment of immune checkpoint inhibitor-associated enterocolitis: a systematic review. Dig Dis Sci 67(4):1128–115533770330
66. Marthey L Mateus C Mussini C Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease J Crohns Colitis 2016 10 4 395 401 10.1093/ecco-jcc/jjv227 26783344
Marthey L, Mateus C, Mussini C et al (2016) Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10(4):395–40126783344
67. Pagès C Gornet JM Monsel G Ipilimumab-induced acute severe colitis treated by infliximab Melanoma Res 2013 23 3 227 230 10.1097/CMR.0b013e32835fb524 23458760
Pagès C, Gornet JM, Monsel G et al (2013) Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 23(3):227–23023458760
68. Ribas A Kefford R Marshall MA Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J Clin Oncol 2013 31 5 616 622 10.1200/JCO.2012.44.6112 23295794
Ribas A, Kefford R, Marshall MA et al (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616–62223295794
69. Wang DY Salem JE Cohen JV Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis JAMA Oncol 2018 4 12 1721 1728 10.1001/jamaoncol.2018.3923 30242316
Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721–172830242316
70. Gupta A De Felice KM Loftus EV Jr Khanna S Systematic review: colitis associated with anti-CTLA-4 therapy Aliment Pharmacol Ther 2015 42 4 406 417 10.1111/apt.13281 26079306
Gupta A, De Felice KM, Loftus EV Jr, Khanna S (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42(4):406–41726079306
71. Wang F Yin Q Chen L Davis MM Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade Proc Natl Acad Sci U S A 2018 115 1 157 161 10.1073/pnas.1712901115 29255057
Wang F, Yin Q, Chen L, Davis MM (2018) Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc Natl Acad Sci U S A 115(1):157–16129255057
72. Vétizou M Pitt JM Daillère R Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota Science 2015 350 6264 1079 1084 10.1126/science.aad1329 26541610
Vétizou M, Pitt JM, Daillère R et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079–108426541610
73. Maruya M Kawamoto S Kato LM Fagarasan S Impaired selection of IgA and intestinal dysbiosis associated with PD-1-deficiency Gut Microbes 2013 4 2 165 171 10.4161/gmic.23595 23333864
Maruya M, Kawamoto S, Kato LM, Fagarasan S (2013) Impaired selection of IgA and intestinal dysbiosis associated with PD-1-deficiency. Gut Microbes 4(2):165–17123333864
74. Sun S Luo L Liang W Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade Proc Natl Acad Sci U S A 2020 117 44 27509 27515 10.1073/pnas.1921223117 33077598
Sun S, Luo L, Liang W et al (2020) Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. Proc Natl Acad Sci U S A 117(44):27509–2751533077598
75. Arboleya S Watkins C Stanton C Ross RP Gut bifidobacteria populations in human health and aging Front Microbiol 2016 7 1204 10.3389/fmicb.2016.01204 27594848
Arboleya S, Watkins C, Stanton C, Ross RP (2016) Gut bifidobacteria populations in human health and aging. Front Microbiol 7:120427594848
76. Pickard JM Zeng MY Caruso R Núñez G Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease Immunol Rev 2017 279 1 70 89 10.1111/imr.12567 28856738
Pickard JM, Zeng MY, Caruso R, Núñez G (2017) Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease. Immunol Rev 279(1):70–8928856738
77. Shi Y Zheng W Yang K Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling J Exp Med 2020 217 5 e20192282 10.1084/jem.20192282 32142585
Shi Y, Zheng W, Yang K et al (2020) Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med 217(5):e2019228232142585
78. Kuugbee ED Shang X Gamallat Y Structural change in microbiota by a probiotic cocktail enhances the gut barrier and reduces cancer via TLR2 signaling in a rat model of colon cancer Dig Dis Sci 2016 61 10 2908 2920 10.1007/s10620-016-4238-7 27384052
Kuugbee ED, Shang X, Gamallat Y et al (2016) Structural change in microbiota by a probiotic cocktail enhances the gut barrier and reduces cancer via TLR2 signaling in a rat model of colon cancer. Dig Dis Sci 61(10):2908–292027384052
79. Ruiz de la Bastida A Peirotén Á Langa S Fermented soy beverages as vehicle of probiotic lactobacilli strains and source of bioactive isoflavones: a potential double functional effect Heliyon 2023 9 4 e14991 10.1016/j.heliyon.2023.e14991 37095934
Ruiz de la Bastida A, Peirotén Á, Langa S et al (2023) Fermented soy beverages as vehicle of probiotic lactobacilli strains and source of bioactive isoflavones: a potential double functional effect. Heliyon 9(4):e1499137095934
80. Wei C Xun AY Wei XX Bifidobacteria expressing tumstatin protein for antitumor therapy in tumor-bearing mice Technol Cancer Res Treat 2016 15 3 498 508 10.1177/1533034615581977 25969440
Wei C, Xun AY, Wei XX et al (2016) Bifidobacteria expressing tumstatin protein for antitumor therapy in tumor-bearing mice. Technol Cancer Res Treat 15(3):498–50825969440
81. Lathrop SK Bloom SM Rao SM Peripheral education of the immune system by colonic commensal microbiota Nature 2011 478 7368 250 254 10.1038/nature10434 21937990
Lathrop SK, Bloom SM, Rao SM et al (2011) Peripheral education of the immune system by colonic commensal microbiota. Nature 478(7368):250–25421937990
82. Niers LE Hoekstra MO Timmerman HM Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells Clin Exp Immunol 2007 149 2 344 352 10.1111/j.1365-2249.2007.03421.x 17521319
Niers LE, Hoekstra MO, Timmerman HM et al (2007) Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. Clin Exp Immunol 149(2):344–35217521319
83. Li Q Li Y Wang Y Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12 Oncoimmunology 2021 10 1 1868122 10.1080/2162402X.2020.1868122 33537172
Li Q, Li Y, Wang Y et al (2021) Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12. Oncoimmunology 10(1):186812233537172
84. Choi M Lee Y Lee NK Immunomodulatory effects by Bifidobacterium longum KACC 91563 in mouse splenocytes and macrophages J Microbiol Biotechnol 2019 29 11 1739 1744 10.4014/jmb.1812.12002 31546293
Choi M, Lee Y, Lee NK et al (2019) Immunomodulatory effects by Bifidobacterium longum KACC 91563 in mouse splenocytes and macrophages. J Microbiol Biotechnol 29(11):1739–174431546293
85. Moussu H Van Overtvelt L Horiot S Bifidobacterium bifidum NCC 453 promotes tolerance induction in murine models of sublingual immunotherapy Int Arch Allergy Immunol 2012 158 1 35 42 10.1159/000330101 22205338
Moussu H, Van Overtvelt L, Horiot S et al (2012) Bifidobacterium bifidum NCC 453 promotes tolerance induction in murine models of sublingual immunotherapy. Int Arch Allergy Immunol 158(1):35–4222205338
86. Hayase E Jenq RR Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer Genome Med 2021 13 1 107 10.1186/s13073-021-00923-w 34162429
Hayase E, Jenq RR (2021) Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Med 13(1):10734162429
87. Luo B Zhang Y Zhang C Liu X Shi C Intestinal microbiota: a potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors Cancer Lett 2021 509 53 62 10.1016/j.canlet.2021.04.001 33845122
Luo B, Zhang Y, Zhang C, Liu X, Shi C (2021) Intestinal microbiota: a potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. Cancer Lett 509:53–6233845122
88. Routy B Le Chatelier E Derosa L Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors Science 2018 359 6371 91 97 10.1126/science.aan3706 29097494
Routy B, Le Chatelier E, Derosa L et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91–9729097494
89. Gopalakrishnan V Helmink BA Spencer CN Reuben A Wargo JA The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy Cancer Cell 2018 33 4 570 580 10.1016/j.ccell.2018.03.015 29634945
Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA (2018) The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 33(4):570–58029634945
90. Kitagawa K Tatsumi M Kato M An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model Mol Ther Oncolytics 2021 22 592 603 10.1016/j.omto.2021.08.009 34589578
Kitagawa K, Tatsumi M, Kato M et al (2021) An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model. Mol Ther Oncolytics 22:592–60334589578
91. Tripodi L Feola S Granata I Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma iScience 2023 26 10 107668 10.1016/j.isci.2023.107668 37720092
Tripodi L, Feola S, Granata I et al (2023) Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma. iScience 26(10):10766837720092
92. Liu X Pu Y Cron K CD47 blockade triggers T cell-mediated destruction of immunogenic tumors Nat Med 2015 21 10 1209 1215 10.1038/nm.3931 26322579
Liu X, Pu Y, Cron K et al (2015) CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21(10):1209–121526322579
93. Shirley JL Keeler GD Sherman A Type I IFN sensing by cDCs and CD4(+) T cell help are both requisite for cross-priming of AAV capsid-specific CD8(+) T Cells Mol Ther 2020 28 3 758 770 10.1016/j.ymthe.2019.11.011 31780366
Shirley JL, Keeler GD, Sherman A et al (2020) Type I IFN sensing by cDCs and CD4(+) T cell help are both requisite for cross-priming of AAV capsid-specific CD8(+) T Cells. Mol Ther 28(3):758–77031780366
94. Curran E Chen X Corrales L STING pathway activation stimulates potent immunity against acute myeloid leukemia Cell Rep 2016 15 11 2357 2366 10.1016/j.celrep.2016.05.023 27264175
Curran E, Chen X, Corrales L et al (2016) STING pathway activation stimulates potent immunity against acute myeloid leukemia. Cell Rep 15(11):2357–236627264175
95. Turroni F Serafini F Foroni E Role of sortase-dependent pili of Bifidobacterium bifidum PRL2010 in modulating bacterium-host interactions Proc Natl Acad Sci U S A 2013 110 27 11151 11156 10.1073/pnas.1303897110 23776216
Turroni F, Serafini F, Foroni E et al (2013) Role of sortase-dependent pili of Bifidobacterium bifidum PRL2010 in modulating bacterium-host interactions. Proc Natl Acad Sci U S A 110(27):11151–1115623776216
96. Bessell CA Isser A Havel JJ Commensal bacteria stimulate antitumor responses via T cell cross-reactivity JCI Insight 2020 5 8 e135597 10.1172/jci.insight.135597 32324171
Bessell CA, Isser A, Havel JJ et al (2020) Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight 5(8):e13559732324171
97. Zitvogel L Kroemer G Cross-reactivity between microbial and tumor antigens Curr Opin Immunol 2022 75 102171 10.1016/j.coi.2022.102171 35219942
Zitvogel L, Kroemer G (2022) Cross-reactivity between microbial and tumor antigens. Curr Opin Immunol 75:10217135219942
98. Ting NL Lau HC Yu J Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes Gut 2022 71 7 1412 1425 10.1136/gutjnl-2021-326264 35277453
Ting NL, Lau HC, Yu J (2022) Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut 71(7):1412–142535277453
99. Lu D Wang L Wang L Probiotic engineering and targeted sonoimmuno-therapy augmented by STING agonist Adv Sci (Weinh) 2022 9 22 e2201711 10.1002/advs.202201711 35603970
Lu D, Wang L, Wang L et al (2022) Probiotic engineering and targeted sonoimmuno-therapy augmented by STING agonist. Adv Sci (Weinh) 9(22):e220171135603970
100. Matson V Chervin CS Gajewski TF Cancer and the Microbiome-influence of the commensal microbiota on cancer, immune responses, and immunotherapy Gastroenterology 2021 160 2 600 613 10.1053/j.gastro.2020.11.041 33253684
Matson V, Chervin CS, Gajewski TF (2021) Cancer and the Microbiome-influence of the commensal microbiota on cancer, immune responses, and immunotherapy. Gastroenterology 160(2):600–61333253684
